Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis

References

• Coiffier B. Treatment of non-Hodgkin lymphoma: a look over the past decade. Clin Lymphoma Myeloma 2006; 7(Suppl. 1)S7–S13
   PubMedGoogle Scholar
• Czuczman M S, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez A J. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 4711–4716
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez A J, Link B K, Levy R, Czuczman M S, Williams M E, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz S F, Cogliatti S B, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 2004; 103: 4416–4423
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Schmitz S F, Cogliatti S, Bertoni F, Waltzer U, Fey M F, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23: 705–711
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, Bock H P, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003–4008
   PubMed Web of Science ®Google Scholar
• van Oers M H, Klasa R, Marcus R E, Wolf M, Kimby E, Gascoyne R D, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295–3301
   PubMed Web of Science ®Google Scholar
• Habermann T M, Weller E A, Morrison V A, Gascoyne R D, Cassileth P A, Cohn J B, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121–3127
   PubMed Web of Science ®Google Scholar
• Hainsworth J D, Litchy S, Burris H A, III, Scullin D C, Jr., Corso S W, Yardley D A, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin lymphoma. J Clin Oncol 2002; 20: 4261–4267
   PubMed Web of Science ®Google Scholar
• Hainsworth J D, Litchy S, Barton J H, Houston G A, Hermann R C, Bradof J E, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21: 1746–1751
   PubMed Web of Science ®Google Scholar
• Del Poeta G, Del Principe M I, Buccisano F, Maurillo L, Capelli G, Luciano F, et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer 2008; 112: 119–128
   PubMed Web of Science ®Google Scholar
• Kahl B S, Longo W L, Eickhoff J C, Zehnder J, Jones C, Blank J, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006; 17: 1418–1423
   PubMed Web of Science ®Google Scholar
• Hainsworth J D. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin lymphoma. Semin Oncol 2003; 30(1 Suppl. 2)9–15
   PubMed Web of Science ®Google Scholar
• Hainsworth J D. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin lymphoma: interim follow-up of a multicenter phase II trial. Semin Oncol 2002; 29(Suppl. 2)25–29
   PubMed Web of Science ®Google Scholar
• Conlan M G, Bast M, Armitage J O, Weisenburger D D. Bone marrow involvement by non-Hodgkin lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol 1990; 8: 1163–1172
   PubMed Web of Science ®Google Scholar
• Morrison V A, Rai K R, Peterson B L, Kolitz J E, Elias L, Appelbaum F R, et al. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol 2001; 19: 3611–3621
   PubMed Web of Science ®Google Scholar
• Byrd J C, McGrail L H, Hospenthal D R, Howard R S, Dow N A, Diehl L F. Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study. Br J Haematol 1999; 105: 445–447
   PubMed Web of Science ®Google Scholar
• Nicholson K G, Kent J, Hammersley V, Cancio E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ 1997; 315: 1060–1064
   PubMed Web of Science ®Google Scholar
• Schouten H C. Neutropenia management. Ann Oncol 2006; 17(Suppl. 10)x85–x89
   PubMed Web of Science ®Google Scholar
• Greil R, Psenak O, Roila F. Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol 2008; 19(Suppl. 2)ii116–ii118
   PubMedGoogle Scholar
• Bodey G P, Buckley M, Sathe Y S, Freireich E J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328–340
   PubMed Web of Science ®Google Scholar
• Rituxan® (rituximab) [package insert] South San Francisco CG, Inc. 2 2006 and Cambridge, MA: Biogen Idec Inc.
   Google Scholar
• Nitta E, Izutsu K, Sato T, Ota Y, Takeuchi K, Kamijo A, et al. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann Oncol 2007; 18: 364–369
   PubMed Web of Science ®Google Scholar
• Cabanillas F, Liboy I, Pavia O, Rivera E. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol 2006; 17: 1424–1427
   PubMed Web of Science ®Google Scholar
• Anolik J H, Friedberg J W, Zheng B, Barnard J, Owen T, Cushing E, et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 2007; 122: 139–145
   PubMed Web of Science ®Google Scholar
• Roll P, Palanichamy A, Kneitz C, Dorner T, Tony H P. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006; 54: 2377–2386
   PubMed Web of Science ®Google Scholar
• Leandro M J, Cambridge G, Ehrenstein M R, Edwards J C. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613–620
   PubMed Web of Science ®Google Scholar
• Horwitz S M, Negrin R S, Blume K G, Breslin S, Stuart M J, Stockerl-Goldstein K E, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103: 777–783
   PubMed Web of Science ®Google Scholar
• van der Kolk L E, Baars J W, Prins M H, van Oers M H. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002; 100: 2257–2259
   PubMed Web of Science ®Google Scholar
• Aksoy S, Abali H, Kilickap S, Erman M, Kars A. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin lymphoma patient. Clin Lab Haematol 2006; 28: 211–214
   PubMedGoogle Scholar
• Aksoy S, Harputluoglu H, Kilickap S, Dede D S, Dizdar O, Altundag K, Barista I. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007; 48: 1307–1312
   PubMed Web of Science ®Google Scholar
• Unluturk U, Aksoy S, Yonem O, Bayraktar Y, Tekuzman G. Cytomegalovirus gastritis after rituximab treatment in a non-Hodgkin lymphoma patient. World J Gastroenterol 2006; 12: 1978–1979
   PubMed Web of Science ®Google Scholar